| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to medicine and describes a pharmaceutical concentration for dissolution before oral introduction, containing S1P receptor modulator or agonist specified in a group involving 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol or proper phosphate, and 1-{4-[1-(4-cyclohexyl-3-trifluoromethylbenzyloxyimino)ethyl]-2-ethylbenzyl}azetidine-3-carboxylic acid, or their pharmaceutically acceptable salts, respectively, and 65 to 99 wt % propylene glycol, and optionally one or more other solvents, one or more aromatisers and/or one or more preserving agents; all the ingredients are added up to 100 wt %. What is also described is a pharmaceutical solution containing the concentrate, the use of the concentrate and the method for treating an individual in need of immune system suppression with the use of said concentrate.EFFECT: invention provides physical stability over long periods of time.9 cl, 6 ex |
